Farther Finance Advisors LLC cut its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 11.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,325 shares of the company’s stock after selling 176 shares during the quarter. Farther Finance Advisors LLC’s holdings in Medpace were worth $440,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the business. R Squared Ltd purchased a new stake in shares of Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. purchased a new stake in Medpace during the 4th quarter valued at approximately $31,000. Stone House Investment Management LLC bought a new stake in shares of Medpace during the third quarter valued at approximately $33,000. Jones Financial Companies Lllp lifted its holdings in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after buying an additional 110 shares in the last quarter. Finally, Lindbrook Capital LLC boosted its position in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after acquiring an additional 29 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.
Medpace Stock Up 2.2 %
Shares of NASDAQ:MEDP opened at $324.95 on Monday. The firm has a fifty day simple moving average of $340.28 and a two-hundred day simple moving average of $340.84. The stock has a market capitalization of $9.90 billion, a P/E ratio of 25.73, a PEG ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77.
Analyst Upgrades and Downgrades
Separately, Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus price target of $381.44.
Check Out Our Latest Report on MEDP
Medpace Company Profile
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Read More
- Five stocks we like better than Medpace
- There Are Different Types of Stock To Invest In
- How to Build the Ultimate Everything ETF Portfolio
- How to Invest in Biotech Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Invest in Small Cap StocksĀ
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.